{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:52:23Z","timestamp":1782337943314,"version":"3.54.5"},"reference-count":103,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Glioblastoma Multiforme (GBM) is a debilitating type of brain cancer with a high mor-tality rate. Despite current treatment options such as surgery, radiotherapy, and the use of te-mozolomide and bevacizumab, it is considered incurable. Various methods, such as drug reposition-ing, have been used to increase the number of available treatments. Drug repositioning is the use of FDA-approved drugs to treat other diseases. This is possible because the drugs used for this purpose have polypharmacological effects. This means that these medications can bind to multiple targets, resulting in multiple mechanisms of action. Antipsychotics are one type of drug used to treat GBM. Antipsychotics are a broad class of drugs that can be further subdivided into typical and atypical classes. Typical antipsychotics include chlorpromazine, trifluoperazine, and pimozide. This class of antipsychotics was developed early on and primarily works on dopamine D2 receptors, though it can also work on others. Olanzapine and Quetiapine are examples of atypical antipsychotics, a cate-gory that was created later. These medications have a high affinity for serotonin receptors such as 5-HT2, but they can also act on dopamine and H1 receptors. Antipsychotic medications, in the case of GBM, also have other effects that can affect multiple pathways due to their polypharmacological effects. These include NF-B suppression, cyclin deregulation, and -catenin phosphorylation, among others. This review will delve deeper into the polypharmacological, the multiple effects of antipsy-chotics in the treatment of GBM, and an outlook for the field's future progression.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230102095836","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T04:27:26Z","timestamp":1672720046000},"page":"389-402","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma\nTreatment"],"prefix":"10.2174","volume":"23","author":[{"given":"Wireko Andrew","family":"Awuah","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Sumy State University, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"first","affiliation":[{"name":"Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia"},{"name":"AFNP Med, 1030 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kalmanovich","sequence":"additional","affiliation":[{"name":"College of Medicine, Drexel University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna","family":"Mehta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Huang","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufik","family":"Abdul-Rahman","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Sumy State University, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyi","family":"Cheng  Ng","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Putra Malaysia, Serdang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Yarlagadda","sequence":"additional","affiliation":[{"name":"School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kamanousa","sequence":"additional","affiliation":[{"name":"College of Medicine, Drexel University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinmoy","family":"Kundu","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Patience","family":"Nansubuga","sequence":"additional","affiliation":[{"name":"Leeds Medical School, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehedi","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykola","family":"Lyndin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Sumy State University, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Isik","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Istanbul Medeniyet University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladyslav","family":"Sikora","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Sumy State University, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1073\/pnas.97.12.6242","volume":"97","author":"Holland E.C.","year":"2000","unstructured":"Holland E.C.; Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA 2000,97(12),6242-6244","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1101\/gad.891601","volume":"15","author":"Maher E.A.","year":"2001","unstructured":"Maher E.A.; Furnari F.B.; Bachoo R.M.; Rowitch D.H.; Louis D.N.; Cavenee W.K.; DePinho R.A.; Malignant glioma: Genetics and biology of a grave matter. Genes Dev 2001,15(11),1311-1333","journal-title":"Genes Dev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ncpneuro0289","volume":"2","author":"Schwartzbaum J.A.","year":"2006","unstructured":"Schwartzbaum J.A.; Fisher J.L.; Aldape K.D.; Wrensch M.; Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006,2(9),494-516","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","volume":"61","author":"Agnihotri S.","year":"2013","unstructured":"Agnihotri S.; Burrell K.E.; Wolf A.; Jalali S.; Hawkins C.; Rutka J.T.; Zadeh G.; Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2013,61(1),25-41","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","volume":"109","author":"Ohgaki H.","year":"2005","unstructured":"Ohgaki H.; Kleihues P.; Epidemiology and etiology of gliomas. Acta Neuropathol 2005,109(1),93-108","journal-title":"Acta Neuropathol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jocn.2009.09.004","volume":"17","author":"Tran B.","year":"2010","unstructured":"Tran B.; Rosenthal M.A.; Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010,17(4),417-421","journal-title":"J Clin Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"878425","DOI":"10.1155\/2012\/878425","volume":"2012","author":"Ohka F.","year":"2012","unstructured":"Ohka F.; Natsume A.; Wakabayashi T.; Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int 2012,2012,878425","journal-title":"Neurol Res Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3171\/2018.12.JNS182558","volume":"132","author":"Roh T.H.","year":"2020","unstructured":"Roh T.H.; Kang S.G.; Moon J.H.; Sung K.S.; Park H.H.; Kim S.H.; Kim E.H.; Hong C.K.; Suh C.O.; Chang J.H.; Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: A retrospective study. J Neurosurg 2020,132(3),895-901","journal-title":"J Neurosurg"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"603911","DOI":"10.3389\/fimmu.2020.603911","volume":"11","author":"Huang B.","year":"2021","unstructured":"Huang B.; Li X.; Li Y.; Zhang J.; Zong Z.; Zhang H.; Current immunotherapies for glioblastoma multiforme. Front Immunol 2021,11,603911","journal-title":"Front Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/neuonc\/4.4.278","volume":"4","author":"Wrensch M.","year":"2002","unstructured":"Wrensch M.; Minn Y.; Chew T.; Bondy M.; Berger M.S.; Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-oncol 2002,4(4),278-299","journal-title":"Neuro-oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"Louis D.N.","year":"2007","unstructured":"Louis D.N.; Ohgaki H.; Wiestler O.D.; Cavenee W.K.; Burger P.C.; Jouvet A.; Scheithauer B.W.; Kleihues P.; The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007,114(2),97-109","journal-title":"Acta Neuropathol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"Wen P.Y.","year":"2008","unstructured":"Wen P.Y.; Kesari S.; Malignant gliomas in adults. N Engl J Med 2008,359(5),492-507","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.soncn.2018.10.001","volume":"34","author":"Davis M.E.","year":"2018","unstructured":"Davis M.E.; Epidemiology and overview of gliomas. Semin Oncol Nurs 2018,34(5),420-429","journal-title":"Semin Oncol Nurs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","volume":"35","author":"Sulman E.P.","year":"2017","unstructured":"Sulman E.P.; Ismaila N.; Armstrong T.S.; Tsien C.; Batchelor T.T.; Cloughesy T.; Galanis E.; Gilbert M.; Gondi V.; Lovely M.; Mehta M.; Mumber M.P.; Sloan A.; Chang S.M.; Radiation therapy for glioblastoma: American society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology guideline. J Clin Oncol 2017,35(3),361-369","journal-title":"J Clin Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"Nabors L.B.","year":"2020","unstructured":"Nabors L.B.; Portnow J.; Ahluwalia M.; Baehring J.; Brem H.; Brem S.; Butowski N.; Campian J.L.; Clark S.W.; Fabiano A.J.; Forsyth P.; Hattangadi-Gluth J.; Holdhoff M.; Horbinski C.; Junck L.; Kaley T.; Kumthekar P.; Loeffler J.S.; Mrugala M.M.; Nagpal S.; Pandey M.; Parney I.; Peters K.; Puduvalli V.K.; Robins I.; Rockhill J.; Rusthoven C.; Shonka N.; Shrieve D.C.; Swinnen L.J.; Weiss S.; Wen P.Y.; Willmarth N.E.; Bergman M.A.; Darlow S.D.; Central nervous system cancers, version 3.2020, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020,18(11),1537-1570","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2020.10.050","volume":"499","author":"Jiang T.","year":"2021","unstructured":"Jiang T.; Nam D.H.; Ram Z.; Poon W.; Wang J.; Boldbaatar D.; Mao Y.; Ma W.; Mao Q.; You Y.; Jiang C.; Yang X.; Kang C.; Qiu X.; Li W.; Li S.; Chen L.; Li X.; Liu Z.; Wang W.; Bai H.; Yao Y.; Li S.; Wu A.; Sai K.; Li G.; Yao K.; Wei X.; Liu X.; Zhang Z.; Dai Y.; Lv S.; Wang L.; Lin Z.; Dong J.; Xu G.; Ma X.; Zhang W.; Zhang C.; Chen B.; You G.; Wang Y.; Wang Y.; Bao Z.; Yang P.; Fan X.; Liu X.; Zhao Z.; Wang Z.; Li Y.; Wang Z.; Li G.; Fang S.; Li L.; Liu Y.; Liu S.; Shan X.; Liu Y.; Chai R.; Hu H.; Chen J.; Yan W.; Cai J.; Wang H.; Chen L.; Yang Y.; Wang Y.; Han L.; Wang Q.; Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 2021,499,60-72","journal-title":"Cancer Lett"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41571-022-00623-3","volume":"19","author":"Weller M.","year":"2022","unstructured":"Weller M.; van den Bent M.; Preusser M.; Le Rhun E.; Tonn J.C.; Minniti G.; Bendszus M.; Balana C.; Chinot O.; Dirven L.; French P.; Hegi M.E.; Jakola A.S.; Platten M.; Roth P.; Rud&#xE0; R.; Short S.; Smits M.; Taphoorn M.J.B.; von Deimling A.; Westphal M.; Soffietti R.; Reifenberger G.; Wick W.; Author correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2022,19(5),357-358","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","volume":"7","author":"Stummer W.","year":"2006","unstructured":"Stummer W.; Pichlmeier U.; Meinel T.; Wiestler O.D.; Zanella F.; Reulen H.J.; Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006,7(5),392-401","journal-title":"Lancet Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11060-020-03607-4","volume":"150","author":"Farrell C.","year":"2020","unstructured":"Farrell C.; Shi W.; Bodman A.; Olson J.J.;  Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. J Neurooncol 2020,150(2),269-359","journal-title":"J Neurooncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"Stupp R.","year":"2009","unstructured":"Stupp R.; Hegi M.E.; Mason W.P.; van den Bent M.J.; Taphoorn M.J.B.; Janzer R.C.; Ludwin S.K.; Allgeier A.; Fisher B.; Belanger K.; Hau P.; Brandes A.A.; Gijtenbeek J.; Marosi C.; Vecht C.J.; Mokhtari K.; Wesseling P.; Villa S.; Eisenhauer E.; Gorlia T.; Weller M.; Lacombe D.; Cairncross J.G.; Mirimanoff R.O.; Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009,10(5),459-466","journal-title":"Lancet Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"Malmstr&#xF6;m A.","year":"2012","unstructured":"Malmstr&#xF6;m A.; Gr&#xF8;nberg B.H.; Marosi C.; Stupp R.; Frappaz D.; Schultz H.; Abacioglu U.; Tavelin B.; Lhermitte B.; Hegi M.E.; Rosell J.; Henriksson R.; Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012,13(9),916-926","journal-title":"Lancet Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00701-014-2073-1","volume":"156","author":"Eigenbrod S.","year":"2014","unstructured":"Eigenbrod S.; Trabold R.; Brucker D.; Er&#xF6;s C.; Egensperger R.; La Fougere C.; G&#xF6;bel W.; R&#xFC;hm A.; Kretzschmar H.A.; Tonn J.C.; Herms J.; Giese A.; Kreth F.W.; Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir 2014,156(8),1427-1440","journal-title":"Acta Neurochir"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"Mohile N.A.","year":"2022","unstructured":"Mohile N.A.; Messersmith H.; Gatson N.T.; Hottinger A.F.; Lassman A.; Morton J.; Ney D.; Nghiemphu P.L.; Olar A.; Olson J.; Perry J.; Portnow J.; Schiff D.; Shannon A.; Shih H.A.; Strowd R.; van den Bent M.; Ziu M.; Blakeley J.; Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 2022,40(4),403-426","journal-title":"J Clin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"Perry J.R.","year":"2017","unstructured":"Perry J.R.; Laperriere N.; O\u2019Callaghan C.J.; Brandes A.A.; Menten J.; Phillips C.; Fay M.; Nishikawa R.; Cairncross J.G.; Roa W.; Osoba D.; Rossiter J.P.; Sahgal A.; Hirte H.; Laigle-Donadey F.; Franceschi E.; Chinot O.; Golfinopoulos V.; Fariselli L.; Wick A.; Feuvret L.; Back M.; Tills M.; Winch C.; Baumert B.G.; Wick W.; Ding K.; Mason W.P.; Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017,376(11),1027-1037","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"Ostrom Q.T.","year":"2019","unstructured":"Ostrom Q.T.; Cioffi G.; Gittleman H.; Patil N.; Waite K.; Kruchko C.; Barnholtz-Sloan J.S.; CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2012\u20132016. Neuro-oncol 2019,21(S5),v1-v100","journal-title":"Neuro-oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003088-200645090-00002","volume":"45","author":"Motl S.","year":"2006","unstructured":"Motl S.; Zhuang Y.; Waters C.M.; Stewart C.F.; Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 2006,45(9),871-903","journal-title":"Clin Pharmacokinet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"Muldoon L.L.","year":"2007","unstructured":"Muldoon L.L.; Soussain C.; Jahnke K.; Johanson C.; Siegal T.; Smith Q.R.; Hall W.A.; Hynynen K.; Senter P.D.; Peereboom D.M.; Neuwelt E.A.; Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 2007,25(16),2295-2305","journal-title":"J Clin Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrd2368","volume":"6","author":"Cecchelli R.","year":"2007","unstructured":"Cecchelli R.; Berezowski V.; Lundquist S.; Culot M.; Renftel M.; Dehouck M.P.; Fenart L.; Modelling of the blood\u2013brain barrier in drug discovery and development. Nat Rev Drug Discov 2007,6(8),650-661","journal-title":"Nat Rev Drug Discov"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00228-009-0714-8","volume":"65","author":"Urquhart B.L.","year":"2009","unstructured":"Urquhart B.L.; Kim R.B.; Blood\u2212brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009,65(11),1063-1070","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc1889","volume":"6","author":"Vescovi A.L.","year":"2006","unstructured":"Vescovi A.L.; Galli R.; Reynolds B.A.; Brain tumour stem cells. Nat Rev Cancer 2006,6(6),425-436","journal-title":"Nat Rev Cancer"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"Clarke M.F.","year":"2006","unstructured":"Clarke M.F.; Dick J.E.; Dirks P.B.; Eaves C.J.; Jamieson C.H.M.; Jones D.L.; Visvader J.; Weissman I.L.; Wahl G.M.; Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006,66(19),9339-9344","journal-title":"Cancer Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cell.2012.03.009","volume":"149","author":"Chen J.","year":"2012","unstructured":"Chen J.; McKay R.M.; Parada L.F.; Malignant glioma: Lessons from genomics, mouse models, and stem cells. Cell 2012,149(1),36-47","journal-title":"Cell"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/v12091058","volume":"12","author":"Low Z.Y.","year":"2020","unstructured":"Low Z.Y.; Farouk I.A.; Lal S.K.; Drug repositioning: New approaches and future prospects for life-debilitating diseases and the covid-19 pandemic outbreak. Viruses 2020,12(9),1058","journal-title":"Viruses"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fphar.2018.00218","volume":"9","author":"Tan S.K.","year":"2018","unstructured":"Tan S.K.; Jermakowicz A.; Mookhtiar A.K.; Nemeroff C.B.; Sch&#xFC;rer S.C.; Ayad N.G.; Drug repositioning in glioblastoma: A pathway perspective. Front Pharmacol 2018,9,218","journal-title":"Front Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3892\/ol.2016.4074","volume":"11","author":"Lee J.K.","year":"2016","unstructured":"Lee J.K.; Nam D.H.; Lee J.; Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. Oncol Lett 2016,11(2),1281-1286","journal-title":"Oncol Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/cncr.21574","volume":"104","author":"Barak Y.","year":"2005","unstructured":"Barak Y.; Achiron A.; Mandel M.; Mirecki I.; Aizenberg D.; Reduced cancer incidence among patients with schizophrenia. Cancer 2005,104(12),2817-2821","journal-title":"Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2011.02.018","volume":"129","author":"Chou F.H.C.","year":"2011","unstructured":"Chou F.H.C.; Tsai K.Y.; Su C.Y.; Lee C.C.; The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study. Schizophr Res 2011,129(2-3),97-103","journal-title":"Schizophr Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1017\/S204579602000044X","volume":"29","author":"Pettersson D.","year":"2020","unstructured":"Pettersson D.; Gissler M.; H&#xE4;llgren J.; &#xD6;sby U.; Westman J.; Bobo W.V.; The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: A population-based cohort study. Epidemiol Psychiatr Sci 2020,29,e132","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.3390\/ijms19103105","volume":"19","author":"Kondej M.","year":"2018","unstructured":"Kondej M.; St\u0119pnicki, P.; Kaczor, A.A. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci 2018,19(10),3105","journal-title":"Int J Mol Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","volume":"34","author":"Shin S.Y.","year":"2013","unstructured":"Shin S.Y.; Lee K.S.; Choi Y.K.; Lim H.J.; Lee H.G.; Lim Y.; Lee Y.H.; The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells. Carcinogenesis 2013,34(9),2080-2089","journal-title":"Carcinogenesis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","volume":"68","author":"Kaushik I.","year":"2021","unstructured":"Kaushik I.; Ramachandran S.; Prasad S.; Srivastava S.K.; Drug rechanneling: A novel paradigm for cancer treatment. Semin Cancer Biol 2021,68,279-290","journal-title":"Semin Cancer Biol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"Paul S.M.","year":"2010","unstructured":"Paul S.M.; Mytelka D.S.; Dunwiddie C.T.; Persinger C.C.; Munos B.H.; Lindborg S.R.; Schacht A.L.; How to improve R and D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov 2010,9(3),203-214","journal-title":"Nat Rev Drug Discov"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"Hay M.","year":"2014","unstructured":"Hay M.; Thomas D.W.; Craighead J.L.; Economides C.; Rosenthal J.; Clinical development success rates for investigational drugs. Nat Biotechnol 2014,32(1),40-51","journal-title":"Nat Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.schres.2017.08.065","volume":"195","author":"Li H.","year":"2018","unstructured":"Li H.; Li J.; Yu X.; Zheng H.; Sun X.; Lu Y.; Zhang Y.; Li C.; Bi X.; The incidence rate of cancer in patients with schizophrenia: A meta-analysis of cohort studies. Schizophr Res 2018,195,519-528","journal-title":"Schizophr Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/biomedicines9121785","volume":"9","author":"Vlachos N.","year":"2021","unstructured":"Vlachos N.; Lampros M.; Voulgaris S.; Alexiou G.A.; Repurposing antipsychotics for cancer treatment. Biomedicines 2021,9(12),1785","journal-title":"Biomedicines"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1600-0447.1992.tb10325.x","volume":"85","author":"Mortensen P.B.","year":"1992","unstructured":"Mortensen P.B.; Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients. Acta Psychiatr Scand 1992,85(5),390-393","journal-title":"Acta Psychiatr Scand"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12904-020-00559-4","volume":"19","author":"Saudemont G.","year":"2020","unstructured":"Saudemont G.; Prod\u2019Homme C.; Da Silva A.; Villet S.; Reich M.; Penel N.; Gamblin V.; The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care 2020,19(1),56","journal-title":"BMC Palliat Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.npp.1300603","volume":"30","author":"Dazzan P.","year":"2005","unstructured":"Dazzan P.; Morgan K.D.; Orr K.; Hutchinson G.; Chitnis X.; Suckling J.; Fearon P.; McGuire P.K.; Mallett R.M.; Jones P.B.; Leff J.; Murray R.M.; Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005,30(4),765-774","journal-title":"Neuropsychopharmacology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2021.12.014","volume":"527","author":"You F.","year":"2022","unstructured":"You F.; Zhang C.; Liu X.; Ji D.; Zhang T.; Yu R.; Gao S.; Drug repositioning: Using psychotropic drugs for the treatment of glioma. Cancer Lett 2022,527,140-149","journal-title":"Cancer Lett"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2019.01262","volume":"10","author":"Zhuo C.","year":"2019","unstructured":"Zhuo C.; Xun Z.; Hou W.; Ji F.; Lin X.; Tian H.; Zheng W.; Chen M.; Liu C.; Wang W.; Chen C.; Surprising anticancer activities of psychiatric medications: old drugs offer new hope for patients with brain cancer. Front Pharmacol 2019,10,1262","journal-title":"Front Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"882","DOI":"10.18632\/oncotarget.1801","volume":"5","author":"Li J.","year":"2014","unstructured":"Li J.; Zhu S.; Kozono D.; Ng K.; Futalan D.; Shen Y.; Akers J.C.; Steed T.; Kushwaha D.; Schlabach M.; Carter B.S.; Kwon C.H.; Furnari F.; Cavenee W.; Elledge S.; Chen C.C.; Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 2014,5(4),882-893","journal-title":"Oncotarget"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/cns.13127","volume":"25","author":"Zhu Y.","year":"2019","unstructured":"Zhu Y.; Zhao Y.F.; Liu R.S.; Xiong Y.J.; Shen X.; Wang Y.; Liang Z.Q.; Olanzapine induced autophagy through suppression of NF\u2010&#x3BA;B activation in human glioma cells. CNS Neurosci Ther 2019,25(9),911-921","journal-title":"CNS Neurosci Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1639-8","volume":"207","author":"Kirk S.L.","year":"2009","unstructured":"Kirk S.L.; Glazebrook J.; Grayson B.; Neill J.C.; Reynolds G.P.; Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology 2009,207(1),119-125","journal-title":"Psychopharmacology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11060-014-1688-7","volume":"122","author":"Karpel-Massler G.","year":"2015","unstructured":"Karpel-Massler G.; Kast R.E.; Westhoff M.A.; Dwucet A.; Welscher N.; Nonnenmacher L.; Hlavac M.; Siegelin M.D.; Wirtz C.R.; Debatin K.M.; Halatsch M.E.; Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide\u2019s antiproliferative effect. J Neurooncol 2015,122(1),21-33","journal-title":"J Neurooncol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3858\/emm.2010.42.5.041","volume":"42","author":"Shin S.Y.","year":"2010","unstructured":"Shin S.Y.; Kim C.G.; Kim S.H.; Kim Y.S.; Lim Y.; Lee Y.H.; Chlorpromazine activates p21 Waf1\/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells. Exp Mol Med 2010,42(5),395-405","journal-title":"Exp Mol Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","volume":"40","author":"Matteoni S.","year":"2021","unstructured":"Matteoni S.; Matarrese P.; Ascione B.; Ricci-Vitiani L.; Pallini R.; Villani V.; Pace A.; Paggi M.G.; Abbruzzese C.; Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. J Exp Clin Cancer Res 2021,40(1),347","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"37568","DOI":"10.18632\/oncotarget.17247","volume":"8","author":"Oliva C.R.","year":"2017","unstructured":"Oliva C.R.; Zhang W.; Langford C.; Suto M.J.; Griguer C.E.; Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. Oncotarget 2017,8(23),37568-37583","journal-title":"Oncotarget"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"635472","DOI":"10.3389\/fonc.2021.635472","volume":"11","author":"Matteoni S.","year":"2021","unstructured":"Matteoni S.; Matarrese P.; Ascione B.; Buccarelli M.; Ricci-Vitiani L.; Pallini R.; Villani V.; Pace A.; Paggi M.G.; Abbruzzese C.; Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with temozolomide in restraining human glioblastoma proliferation in vitro. Front Oncol 2021,11,635472","journal-title":"Front Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"37511","DOI":"10.18632\/oncotarget.16400","volume":"8","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Huang N.; Li H.; Liu S.; Chen X.; Yu S.; Wu N.; Bian X.W.; Shen H.Y.; Li C.; Xiao L.; Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma. Oncotarget 2017,8(23),37511-37524","journal-title":"Oncotarget"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","volume":"10","author":"Pai S.G.","year":"2017","unstructured":"Pai S.G.; Carneiro B.A.; Mota J.M.; Costa R.; Leite C.A.; Barroso-Sousa R.; Kaplan J.B.; Chae Y.K.; Giles F.J.; Wnt\/beta-catenin pathway: Modulating anticancer immune response. J Hematol Oncol 2017,10(1),101","journal-title":"J Hematol Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"Liu P.","year":"2009","unstructured":"Liu P.; Cheng H.; Roberts T.M.; Zhao J.J.; Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009,8(8),627-644","journal-title":"Nat Rev Drug Discov"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000444534","volume":"98","author":"Karbownik M.S.","year":"2016","unstructured":"Karbownik M.S.; Szemraj J.S.; Wieteska, \u0141.; Antczak, A.; G&#xF3;rski, P.; Kowalczyk, E.; Pietras, T. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-PI3K pathway. Pharmacology 2016,98,4-12","journal-title":"Pharmacology"},{"key":"ref=64","first-page":"CD003545","volume":"2004","author":"Marques L.O.","year":"2004","unstructured":"Marques L.O.; Lima M.S.; Soares B.G.O.; Trifluoperazine for schizophrenia. Cochrane Database Syst Rev 2004,2004(1),CD003545","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.clpt.6100069","volume":"81","author":"Yang S-Y.","year":"2007","unstructured":"Yang S-Y.; Kao Yang; Y-H.; Chong, M-Y.; Yang, Y-H.; Chang, W-H.; Lai, C-S. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007,81(4),586-594","journal-title":"Clin Pharmacol Ther"},{"key":"ref=66","author":"Timmins J.M.","year":"2009","unstructured":"Timmins J.M.; Ozcan L.; Seimon T.A.; Li G.; Malagelada C.; Backs J.; Calcium\/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. American Society for Clinical Investigation Available from:  [cited 2022 Jun 9].2009","journal-title":"American Society for Clinical Investigation"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1002\/jcb.26848","volume":"119","author":"Fancy R.M.","year":"2018","unstructured":"Fancy R.M.; Kim H.; Napier T.; Buchsbaum D.J.; Zinn K.R.; Song Y.; Calmodulin antagonist enhances DR5\u2010mediated apoptotic signaling in TRA\u20108 resistant triple negative breast cancer cells. J Cell Biochem 2018,119(7),6216-6230","journal-title":"J Cell Biochem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/NEN.0000000000000126","volume":"73","author":"Brosius S.N.","year":"2014","unstructured":"Brosius S.N.; Turk A.N.; Byer S.J.; Longo J.F.; Kappes J.C.; Roth K.A.; Carroll S.L.; Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades. J Neuropathol Exp Neurol 2014,73(11),1078-1090","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/ijms21030765","volume":"21","author":"Villalobo A.","year":"2020","unstructured":"Villalobo A.; Berchtold M.W.; The role of calmodulin in tumor cell migration, invasiveness, and metastasis. Int J Mol Sci 2020,21(3),765","journal-title":"Int J Mol Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41419-017-0253-7","volume":"9","author":"Li T.","year":"2018","unstructured":"Li T.; Yi L.; Hai L.; Ma H.; Tao Z.; Zhang C.; Abeysekera I.R.; Zhao K.; Yang Y.; Wang W.; Liu B.; Yu S.; Tong L.; Liu P.; Zhu M.; Ren B.; Lin Y.; Zhang K.; Cheng C.; Huang Y.; Yang X.; The interactome and spatial redistribution feature of Ca2+ receptor protein calmodulin reveals a novel role in invadopodia-mediated invasion. Cell Death Dis 2018,9(3),292","journal-title":"Cell Death Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejmech.2018.03.055","volume":"151","author":"Kang S.","year":"2018","unstructured":"Kang S.; Lee J.M.; Jeon B.; Elkamhawy A.; Paik S.; Hong J.; Oh S.J.; Paek S.H.; Lee C.J.; Hassan A.H.E.; Kang S.S.; Roh E.J.; Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. Eur J Med Chem 2018,151,186-198","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09687688209065434","volume":"4","author":"Haynes D.H.","year":"1982","unstructured":"Haynes D.H.; Werber M.M.; Inhibition of the Ca2+-Mg2+ ATPase of sarcoplasmic reticulum by Co-(phen)-ATP. Membr Biochem 1982,4(4),247-257","journal-title":"Membr Biochem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ccell.2016.05.002","volume":"29","author":"Dolma S.","year":"2016","unstructured":"Dolma S.; Selvadurai H.J.; Lan X.; Lee L.; Kushida M.; Voisin V.; Whetstone H.; So M.; Aviv T.; Park N.; Zhu X.; Xu C.; Head R.; Rowland K.J.; Bernstein M.; Clarke I.D.; Bader G.; Harrington L.; Brumell J.H.; Tyers M.; Dirks P.B.; Inhibition of dopamine receptor d4 impedes autophagic flux, proliferation, and survival of glioblastoma stem cells. Cancer Cell 2016,29(6),859-873","journal-title":"Cancer Cell"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"11085","DOI":"10.1073\/pnas.1920154117","volume":"117","author":"Kruttika B.","year":"2020","unstructured":"Kruttika B.; Mohammad S.; Erina V.; Frank P.; The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. PNAS 2020,117(20),11085-11096","journal-title":"PNAS"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-11-0767","volume":"18","author":"Botrugno O.A.","year":"2012","unstructured":"Botrugno O.A.; Robert T.; Vanoli F.; Foiani M.; Minucci S.; Molecular pathways: Old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. Clin Cancer Res 2012,18(9),2436-2442","journal-title":"Clin Cancer Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.mrgentox.2007.05.011","volume":"633","author":"Gangopadhyay S.","year":"2007","unstructured":"Gangopadhyay S.; Karmakar P.; Dasgupta U.; Chakraborty A.; Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair. Mutat Res Genet Toxicol Environ Mutagen 2007,633(2),117-125","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"ref=77","first-page":"1","author":"Davis C.","year":"2007","unstructured":"Davis C.; Pimozide. xPharm: The Comprehensive Pharmacology Reference 2007,1-5","journal-title":"xPharm: The Comprehensive Pharmacology Reference"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-803161-2.00018-7","volume":"29","author":"Gopalakrishnan M.","year":"2019","unstructured":"Gopalakrishnan M.; Gobburu J.V.S.; Regulatory perspectives on the use of biomarkers and personalized medicine in cns drug development: The FDA viewpoint. Handbook of Behavioral Neuroscience Available from: 2019,29,247-58","journal-title":"Handbook of Behavioral Neuroscience"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-197612010-00001","volume":"12","author":"Pinder R.M.","year":"1976","unstructured":"Pinder R.M.; Brogden R.N.; Sawyer P.R.; Speight T.M.; Spencer R.; Avery G.S.; Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976,12(1),1-40","journal-title":"Drugs"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1034\/j.1600-0773.2003.930106.x","volume":"93","author":"Silva M.R.","year":"2003","unstructured":"Silva M.R.; Bernardi M.M.; Cruz-Casallas P.E.; Felicio L.F.; Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats. Pharmacology and Toxicology 2003,93(1),42-47","journal-title":"Pharmacology and Toxicology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fpsyt.2019.00314","volume":"10","author":"Amato D.","year":"2019","unstructured":"Amato D.; Kruyer A.; Samaha A.N.; Heinz A.; Hypofunctional dopamine uptake and antipsychotic treatment-resistant schizophrenia. Front Psychiatry 2019,10,314","journal-title":"Front Psychiatry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","volume":"27","author":"Svensson T.H.","year":"2003","unstructured":"Svensson T.H.; &#x3B1;-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003,27(7),1145-1158","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/00004714-200204000-00009","volume":"22","author":"Desta Z.","year":"2002","unstructured":"Desta Z.; Soukhova N.; Flockhart D.A.; In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. J Clin Psychopharmacol 2002,22(2),162-168","journal-title":"J Clin Psychopharmacol"},{"key":"ref=84","first-page":"1403","volume":"268","author":"Roth B.L.","year":"1994","unstructured":"Roth B.L.; Craigo S.C.; Choudhary M.S.; Uluer A.; Monsma F.J.; Shen Y.; Meltzer H.Y.; Sibley D.R.; Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994,268(3),1403-1410","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/hipo.20938","volume":"22","author":"Roberts A.J.","year":"2012","unstructured":"Roberts A.J.; Hedlund P.B.; The 5-HT7 receptor in learning and memory. Hippocampus 2012,22(4),762-771","journal-title":"Hippocampus"},{"key":"ref=86","first-page":"715","volume":"1","author":"Aghajanian G.","year":"2010","unstructured":"Aghajanian G.; Liu R.J.; Serotonin (5-Hydroxytryptamine; 5-HT): CNS pathways and neurophysiology. Encycloped Neurosci 2010,1,715-722","journal-title":"Encycloped Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/1440-1681.13049","volume":"46","author":"Gon&#xE7;alves J.M.","year":"2019","unstructured":"Gon&#xE7;alves J.M.; Silva C.A.B.; Rivero E.R.C.; Cordeiro M.M.R.; Inhibition of cancer stem cells promoted by Pimozide. Clin Exp Pharmacol Physiol 2019,46(2),116-125","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/1097-0142(19820315)49:6<1178:AID-CNCR2820490619>3.0.CO;2-H","volume":"49","author":"Krummel T.M.","year":"1982","unstructured":"Krummel T.M.; Neifeld J.P.; Taub R.N.; Effects of dopamine agonists and antagonists on murine melanoma: Correlation with dopamine binding activity. Cancer 1982,49(6),1178-1184","journal-title":"Cancer"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2019.10.007","volume":"68","author":"Shaw V.","year":"2021","unstructured":"Shaw V.; Srivastava S.; Srivastava S.K.; Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Semin Cancer Biol 2021,68,75-83","journal-title":"Semin Cancer Biol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3892\/ijo.2015.3229","volume":"48","author":"Zhou W.","year":"2016","unstructured":"Zhou W.; Chen M.K.; Yu H.T.; Zhong Z.H.; Cai N.; Chen G.Z.; Zhang P.; Chen J.J.; The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation. Int J Oncol 2016,48(1),322-328","journal-title":"Int J Oncol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/nov091","volume":"18","author":"Lee J.K.","year":"2016","unstructured":"Lee J.K.; Chang N.; Yoon Y.; Yang H.; Cho H.; Kim E.; Shin Y.; Kang W.; Oh Y.T.; Mun G.I.; Joo K.M.; Nam D.H.; Lee J.; USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. Neuro-oncol 2016,18(1),37-47","journal-title":"Neuro-oncol"},{"key":"ref=92","first-page":"429","volume":"30","author":"Miracco C.","year":"2007","unstructured":"Miracco C.; Cosci E.; Oliveri G.; Luzi P.; Pacenti L.; Monciatti I.; Mannucci S.; De Nisi M.C.; Toscano M.; Malagnino V.; Falzarano S.M.; Pirtoli L.; Tosi P.; Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 2007,30(2),429-436","journal-title":"Int J Oncol"},{"key":"ref=93","first-page":"413","volume":"32","author":"Ryskalin L.","year":"2017","unstructured":"Ryskalin L.; Limanaqi F.; Biagioni F.; Frati A.; Esposito V.; Calierno M.T.; Lenzi P.; Fornai F.; The emerging role of m-TOR up-regulation in brain astrocytoma. Histol Histopathol 2017,32(5),413-431","journal-title":"Histol Histopathol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000502562","volume":"105","author":"Weissenrieder J.S.","year":"2020","unstructured":"Weissenrieder J.S.; Reed J.L.; Green M.V.; Moldovan G.L.; Koubek E.J.; Neighbors J.D.; Hohl R.J.; The dopamine d2 receptor contributes to the spheroid formation behavior of u87 glioblastoma cells. Pharmacology 2020,105(1-2),19-27","journal-title":"Pharmacology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12094-016-1509-x","volume":"19","author":"Conde-Est&#xE9;vez D.","year":"2017","unstructured":"Conde-Est&#xE9;vez D.; Targeted cancer therapy: interactions with other medicines. Clin Transl Oncol 2017,19(1),21-30","journal-title":"Clin Transl Oncol"},{"key":"ref=96","first-page":"466","volume":"47","author":"Boone J.L.","year":"1986","unstructured":"Boone J.L.; Patrone N.A.; Daugherty J.E.; Disseminated gonococcal infection and acute pericarditis. N C Med J 1986,47(10),466-467","journal-title":"N C Med J"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/273060","volume":"2014","author":"Khasawneh F.T.","year":"2014","unstructured":"Khasawneh F.T.; Shankar G.S.; Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiol Res Pract 2014,2014,1-8","journal-title":"Cardiol Res Pract"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00702-008-0105-9","volume":"115","author":"Fleischhaker C.","year":"2008","unstructured":"Fleischhaker C.; Heiser P.; Hennighausen K.; Herpertz-Dahlmann B.; Holtkamp K.; Mehler-Wex C.; Rauh R.; Remschmidt H.; Schulz E.; Warnke A.; Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 2008,115(11),1599-1608","journal-title":"J Neural Transm"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"Correll C.U.","year":"2009","unstructured":"Correll C.U.; Manu P.; Olshanskiy V.; Napolitano B.; Kane J.M.; Malhotra A.K.; Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009,302(16),1765-1773","journal-title":"JAMA"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1176\/appi.ps.201100443","volume":"63","author":"Guo J.J.","year":"2012","unstructured":"Guo J.J.; Wu J.; Kelton C.M.L.; Jing Y.; Fan H.; Keck P.E.; Patel N.C.; Exposure to potentially dangerous drug-drug interactions involving antipsychotics. Psychiatr Serv 2012,63(11),1080-1088","journal-title":"Psychiatr Serv"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/pharmacy8020063","volume":"8","author":"Matos A.","year":"2020","unstructured":"Matos A.; Bain K.T.; Bankes D.L.; Furman A.; Skalski B.; Verzicco J.; Turgeon J.; Cytochrome p450 (cyp450) interactions involving atypical antipsychotics are common in community-dwelling older adults treated for behavioral and psychological symptoms of dementia. Pharmacy 2020,8(2),63","journal-title":"Pharmacy"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fphar.2017.00298","volume":"8","author":"March-Vila E.","year":"2017","unstructured":"March-Vila E.; Pinzi L.; Sturm N.; Tinivella A.; Engkvist O.; Chen H.; Rastelli G.; On the integration of in silico drug design methods for drug repurposing. Front Pharmacol 2017,8,298","journal-title":"Front Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"Corsello S.M.","year":"2017","unstructured":"Corsello S.M.; Bittker J.A.; Liu Z.; Gould J.; McCarren P.; Hirschman J.E.; Johnston S.E.; Vrcic A.; Wong B.; Khan M.; Asiedu J.; Narayan R.; Mader C.C.; Subramanian A.; Golub T.R.; The drug repurposing hub: A next-generation drug library and information resource. Nat Med 2017,23(4),405-408","journal-title":"Nat Med"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230102095836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212308\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230102095836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:14:05Z","timestamp":1683112445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212308\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230102095836","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}